Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy

Mandour O Mandour, Anna Stears, Agatha Van Der Klaauw, Catherine Flanagan, Lisa Gaff, Charlotte Jenkins, David B Savage · 2026

Read Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy by Mandour O Mandour, Anna Stears, Agatha Van Der Klaauw, Catherine Flanagan, Lisa Gaff, Charlotte Jenkins, David B Savage (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13466956.txt.

Description

Mandour and colleagues reviewed outcomes in 2026 for tirzepatide, a dual-action diabetes and weight drug, in people with partial lipodystrophy. In this rare condition, missing or faulty fat tissue forces lipids into other organs and drives severe insulin resistance. Treatment options are few, with only one specific licensed drug. Their single-center record review covered all forty patients treated with the drug from 2022 to 2025, most of them women with the commonest inherited subtype.

Over a median follow-up of about nine and a half months, body weight fell by roughly eight kilograms on median values. The long-term blood sugar marker dropped by a wide margin. Blood triglycerides, a fat measure that runs dangerously high in this condition, fell by about a third, and daily insulin needs dropped to about a third of their starting level. The authors call for prospective trials and earlier use studies.

Catalog record

CREATORMandour O Mandour, Anna Stears, Agatha Van Der Klaauw, Catherine Flanagan, Lisa Gaff, Charlotte Jenkins, David B Savage
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13466956

Browse the full library · About the Tower of Babel